NEW YORK, Dec 12 (Reuters) - Merck & Co. (MRK.N: Quote, Profile , Research) on Tuesday said its experimental cholesterol drug MK-859 raised levels of "good" HDL cholesterol by more than 50 percent in clinical trials, without raising blood pressure or causing serious cardiovascular side effects.
